{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:53:16Z","timestamp":1777679596008,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2014,11]]},"abstract":"\n Background<\/jats:title>\n National safety guidelines were developed to minimize the occurrence of serious adverse drug events (ADEs) associated with the use of the fentanyl transdermal system (FTS), however, reports of use in opioid-na\u00efve patients for treatment of acute pain and associated ADEs continue to occur.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the prescribing patterns of the FTS for adherence to recent US regulatory recommendations and identify the impact of health information technology (HIT) on adherence rates.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective pre- and postintervention analysis was performed in hospitalized adult patients receiving FTS. Electronic medication order instructions and text questions were incorporated into FTS electronic medication orders. The primary outcome measure was adherence of FTS medication orders to regulatory guidelines defined as (a) a new order in an opioid-tolerant patient for use in moderate to severe chronic pain or (b) continuation of the documented home dose in use for at least 7 days. Safety measures included respiratory rate and documented ADEs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Adherence rates were significantly increased in the postintervention cohort as compared to the preintervention cohort (48.7% vs 85.0%; P < .0001). Incidence of ADEs was significantly lower post intervention (34.7% vs 23.3%; P = .043), including a lower incidence of respiratory depression (16.7% vs 8.3%; P = .043). Documentation was increased in the postintervention cohort (76% vs 100%). However, supporting documentation confirmed responses in only 59.2% of records reviewed.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Incorporation of HIT via electronic order text questions increased overall adherence rates to regulatory recommendations, increased documentation, and decreased the rate of associated ADEs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1310\/hpj4910-942","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T10:16:32Z","timestamp":1416219392000},"page":"942-949","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Inpatient Prescribing and Monitoring of Fentanyl Transdermal Systems: Adherence to Safety Regulations"],"prefix":"10.1177","volume":"49","author":[{"given":"Theresa","family":"McEvoy","sequence":"first","affiliation":[{"name":"PGY-2 Drug Information Resident at The University of Kansas Hospital, Kansas City, Kansas, at the time the study was conducted."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joann","family":"Moore","sequence":"additional","affiliation":[{"name":"Medication Safety, Department of Pharmacy, The University of Kansas Hospital, Kansas City, Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Generali","sequence":"additional","affiliation":[{"name":"Emeritus, Department of Pharmacy Practice, University of Kansas, School of Pharmacy Kansas City\/Lawrence, Kansas."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"bibr1-hpj4910-942","volume-title":"Duragesic [package insert].","year":"2012"},{"key":"bibr2-hpj4910-942","unstructured":"Information for healthcare professionals: Fentanyl transdermal system (marketed as Duragesic and generics). US Food and Drug Administration Web site. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm084307.htm. Published December 21, 2007. Updated September 30, 2009. Accessed August 28, 2012."},{"key":"bibr3-hpj4910-942","unstructured":"Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). US Food and Drug Administration Web site. http:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/postmarketdrugsafetyinformationfor-patientsandproviders\/ucm311290.pdf. Updated July 2012. Accessed August 28, 2012."},{"key":"bibr4-hpj4910-942","unstructured":"The Joint Commission. Sentinel Event Alert Issue 49: Safe use of opioids in hospitals. August 8, 2012. http:\/\/www.jointcommission.org\/sea_issue_49\/. Accessed August 28, 2012."},{"key":"bibr5-hpj4910-942","unstructured":"KohnL.T. CorriganJ. DonaldsonM.S. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press; 2000. http:\/\/www.iom.edu\/~\/media\/Files\/Report%20Files\/1999\/To-Err-is-Human\/To%20Err%20is%20Human%201999%20%20report%20brief.pdf. Accessed January 5, 2014."},{"key":"bibr6-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530010043033"},{"key":"bibr7-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080488"},{"key":"bibr8-hpj4910-942","unstructured":"The Joint Commission. Sentinel Event Alert, Issue 42: Safely implementing health information and converging technologies. December 11, 2008. http:\/\/www.jointcommission.org\/sentinel_event_alert_issue_42_safely_implementing_health_information_and_converging_technologies\/. Accessed January 5, 2014."},{"key":"bibr9-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0912825"},{"key":"bibr10-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4210-884"},{"key":"bibr11-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0918-0"},{"key":"bibr12-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2008.11.008"},{"key":"bibr13-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2164"},{"key":"bibr14-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4802-112"},{"key":"bibr15-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080552"},{"key":"bibr16-hpj4910-942","unstructured":"National Patient Safety Goals effective January 1, 2014. http:\/\/www.jointcommission.org\/assets\/1\/6\/HAP_NPSG_Chapter_2014.pdf. Accessed February 23, 2014."},{"key":"bibr17-hpj4910-942","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4611-854"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj4910-942","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1310\/hpj4910-942","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj4910-942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:32:57Z","timestamp":1777451577000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1310\/hpj4910-942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1310\/hpj4910-942"],"URL":"https:\/\/doi.org\/10.1310\/hpj4910-942","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}